This was a non-interventional, retrospective registry study, utilizing electronic health record (EHR) data collected in the hospital district of Helsinki and Uusimaa (HUS). Real-world health care resource utilization (HCRU) of AML patients was characterized.
Adult patients (18 years or older) with the inclusion diagnosis, AML (ICD-10 C92.0), between 1.1.2013 - 30.6.2020 were followed from the index date (first ever record of the inclusion diagnosis) until the end of follow-up (30.6.2020), or death. This study did not involve any contacts to patients. The study inclusion period was changed from 1.1.2013 - 30.6.2020 specified in the protocol to 1.1.2016 - 30.6.2020 due to lack of medication data from pre-2016.
Study Type
OBSERVATIONAL
Enrollment
81
Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.
Novartis Investigative Site
Helsinki, Finland
Number of patients initiating midostaurin treatment
Number of patients initiating midostaurin treatment were reported.
Time frame: throughout the study, approximately 5 years
Number of patients who received Midostaurin at induction and consolidation phases
Number of patients who received Midostaurin at induction and consolidation phases were reported.
Time frame: throughout the study, approximately 5 years
Duration of Midostaurin at induction and consolidation phase
Duration of Midostaurin at induction and consolidation phase were reported.
Time frame: throughout the study, approximately 5 years
Median average dose intensity in midostaurin treatment in induction and consolidation phase
Median average dose intensity in midostaurin treatment were reported.
Time frame: throughout the study, approximately 5 years
Most frequent comorbidities at the time of AML diagnosis
Most frequent comorbidities at the time of AML diagnosis were reported.
Time frame: throughout the study, approximately 5 years
Number of patients at the time of diagnosis (All treated AML patients)
Number of patients at the time of diagnosis (All treated AML patients) were reported.
Time frame: throughout the study, approximately 5 years
Number of AML patients receiving midostaurin consolidation treatment in inpatient or outpatient care (based on given prescriptions)
Number of AML patients receiving midostaurin consolidation treatment in inpatient or outpatient care (based on given prescriptions) were reported.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: throughout the study, approximately 5 years
Mean HCRU and related costs in different disease stages
Estimate HCRU and related costs in different disease stages were reported.
Time frame: throughout the study, approximately 5 years